Skip to main content

Table 1 Clinical and pathological data of tissue and urine samples used in this study

From: MiR-193b promoter methylation accurately detects prostate cancer in urine sediments and miR-34b/c or miR-129-2 promoter methylation define subsets of clinically aggressive tumors

 

Prostatectomies

Urine samples

Clinicopathological data

MNPT

PCaa

Controls

PCab

Patients, n

15

180

46

95

Median age, years (range)

63

(45–80)

65

(49–74)

61

(58–77)

64

(45–80)

Median PSA (ng/mL) (range)

-

8.3

(3.4-23.0)

-

8.8

(3.5-20.4)

Pathological Stage

pT2 (%)

-

96 (53.3)

-

46 (48.4)

pT3 (%)

-

84 (46.7)

-

49 (51.6)

Gleason score

<7 (%)

-

56 (31.1)

-

37 (39.0)

≥7 (%)

-

124 (68.9)

-

58 (61.0)

  1. aCohort #1; bCohort #3